“We are excited to welcome a new group of leading life sciences investors on our journey to deliver gene therapy beyond rare disease. Gyroscope said the financing round will also help the company advance its early-stage pipeline and its delivery technology, which includes the proprietary Orbit subretinal delivery system that provides precise delivery of therapeutics to the back of the eye. GT005 has fast-track designation from the FDA and is currently being evaluated in Phase 2 clinical trials. London-based Gyroscope said in a news release that it plans to use the funds raised to advance the clinical development of GT005, the company’s investigational gene therapy designed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In conjunction with the financing, the company announced that Forbion general partner Wouter Joustra and Sofinnova general partner Maha Katabi were appointed to its board of directors. Rowe Price, Tetragon Financial, Fosun Pharma, Cambridge Innovation Capital and Syncona, along with an undisclosed fund, contributed.
GYROSCOPE THERAPEUTICS SERIES
Gyroscope Therapeutics announced today that it raised $148 million (£107.8 million) in a Series C financing round.įorbion’s Growth Opportunities Fund led the round, while Sofinnova Investments, funds and accounts advised by T.
0 kommentar(er)
